National Institute on Drug Abuse » Johns Hopkins Drug Discovery
1307
page-template-default,page,page-id-1307,page-child,parent-pageid-23,ajax_fade,page_not_loaded,,qode-theme-ver-7.7,wpb-js-composer js-comp-ver-4.12.1,vc_responsive

National Institute on Drug Abuse

The Johns Hopkins Drug Discovery Program participates in a highly productive collaboration with Dr. Amy Newman, Director of the Medications Development Program at the National Institute on Drug Abuse (NIDA), Intramural Research Program. By combining NIDA’s expertise in dopamine-related targets with our extensive capabilities in drug metabolism and pharmacokinetics (DMPK), the collaborative project aims to identify novel dopamine D3 receptor ligands and atypical dopamine uptake inhibitors with therapeutic potential in the treatment of drug abuse and addiction.

Recent collaborative publications:

  1. Keck, T. M.; Banala, A. K.; Slack, R. D.; Burzynski, C.; Bonifazi, A.; Okunola-Bakare, O. M.; Moore, M.; Deschamps, J. R.; Rais, R.; Slusher, B. S.; Newman A. H. Using Click Chemistry Toward Novel 1,2,3-triazole-linked Dopamine D3 Receptor Selective Ligands. Bioorg. Med. Chem. 2015, 23 (14) 4000-4012.
  2. Boateng, C. A.; Bakare, O. M.; Zhan, J.; Banala, A. K.; Burzynski, C.; Pommier, E.; Keck, T. M.; Donthamsetti, P.; Javitch, J. A.; Rais, R.; Slusher, B. S.; Xi, Z.-X.; Newman A. H. High Affinity Dopamine D3 Receptor (D3R)-Selective Antagonists Attenuate Heroin Self-administration in Wildtype but not D3R Knockout Mice. J. Med. Chem. 2015, 58(15) 6195-6213.
Visit Site
lowgo_bottom